Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.

被引：11

作者：

Cella, David ^{[1
]}

Choueiri, Toni K. ^{[2
]}

Blum, Steven, I ^{[3
]}

Ejzykowicz, Flavia ^{[3
]}

Hamilton, Melissa ^{[3
]}

Zhang, Joshua ^{[3
]}

Ivanescu, Cristina ^{[4
]}

Motzer, Robert J. ^{[5
]}

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[2] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] IQVIA, Herikerbergweg, Netherlands

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.285

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

285

引用

页数：2

共 50 条

[41] Health-related quality of life (HRQoL) profile and clinical outcomes in first-line (1L) advanced renal cell carcinoma (aRCC): A modelling analysis based on CheckMate 9ER (CM9ER) trial
Bedke, Jens
Giles, Rachel H.
Powles, Thomas
Derosa, Michael
Floden, Lysbeth
Purnajo, Intan
Lothgren, Mickael
Ogareva, Alessia
Cella, David
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 384 - 384
[42] Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Tannir, Nizar M.
Signoretti, Sabina
Choueiri, Toni K.
McDermott, David F.
Motzer, Robert J.
Flaifel, Abdallah
Pignon, Jean-Christophe
Ficial, Miriam
Frontera, Osvaldo Aren
George, Saby
Powles, Thomas
Donskov, Frede
Harrison, Michael R.
Barthelemy, Philippe
Tykodi, Scott S.
Kocsis, Judit
Ravaud, Alain
Rodriguez-Cid, Jeronimo R.
Pal, Sumanta K.
Murad, Andre M.
Ishii, Yuko
Saggi, Shruti Shally
McHenry, M. Brent
Rini, Brian, I
CLINICAL CANCER RESEARCH, 2021, 27 (01) : 78 - 86
[43] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Tannir, Nizar M.
Frontera, Osvaldo Aren
Hammers, Hans J.
Carducci, Michael Anthony
McDermott, David F.
Salman, Pamela
Escudier, Bernard
Beuselinck, Benoit
Amin, Asim
Porta, Camillo
George, Saby
Bracarda, Sergio
Tykodi, Scott S.
Powles, Thomas
Rini, Brian I.
Tomita, Yoshihiko
McHenry, M. Brent
Mekan, Sabeen Fatima
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[44] Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N plus C) versus sunitinib (SUN) in treatment-naive, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.
Cella, David
Motzer, Robert J.
May, Jessica
Wallace, Joel
Marteau, Florence
Kwon, Youngmin
Rusibamayila, Nifasha
Botteman, Marc
Ejzykowicz, Flavia
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[45] A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Choueiri, Toni K.
Apolo, Andrea B.
Powles, Thomas
Escudier, Bernard
Aren, Osvaldo Rudy
Shah, Amishi
Kessler, Elizabeth Riley
Hsieh, James J.
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[46] First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
Albiges, L.
Tannir, N. M.
Burotto, M.
McDermott, D.
Plimack, E. R.
Barthelemy, P.
Porta, C.
Powles, T.
Donskov, F.
George, S.
Kollmannsberger, C. K.
Gurney, H.
Grimm, M. -O.
Tomita, Y.
Castellano, D.
Rini, B. I.
Choueiri, T. K.
Leung, D.
Saggi, S. S.
Lee, C. -W.
McHenry, M. B.
Motzer, R. J.
JOURNAL OF UROLOGY, 2023, 209 (02) : 442 - +
[47] First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
Albiges, Laurence
Tannir, Nizar M.
Burotto, Mauricio
McDermott, David
Plimack, Elizabeth R.
Barthelemy, Philippe
Porta, Camillo
Powles, Thomas
Donskov, Frede
George, Saby
Kollmannsberger, Christian K.
Gurney, Howard
Grimm, Marc-Oliver
Tomita, Yoshihiko
Castellano, Daniel
Rini, Brian, I
Choueiri, Toni K.
Leung, David
Saggi, Shruti Shally
Lee, Chung-Wei
McHenry, M. Brent
Motzer, Robert J.
EUROPEAN UROLOGY, 2022, 81 (03) : 266 - 271
[48] Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma
Liu, Tong
Jin, Yao
Dong, Mei
CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : E449 - E460
[49] Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
Powles, Thomas
Choueiri, Toni K.
Burotto, Mauricio
Escudier, Bernard
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Hamzaj, Alketa
Porta, Camillo
Hocking, Christopher
Kessler, Elizabeth R.
Gurney, Howard
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Apolo, Andrea B.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[50] First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
Scherpereel, Arnaud
Antonia, Scott
Bautista, Yolanda
Grossi, Francesco
Kowalski, Dariusz
Zalcman, Gerard
Nowak, Anna K.
Fujimoto, Nobukazu
Peters, Solange
Tsao, Anne S.
Mansfield, Aaron S.
Popat, Sanjay
Sun, Xiaowu
Lawrance, Rachael
Zhang, Xiaoqing
Daumont, Melinda J.
Bennett, Bryan
McKenna, Mike
Baas, Paul
LUNG CANCER, 2022, 167 : 8 - 16

← 1 2 3 4 5 →